Biochemical and Biophysical Research Communications
Regular ArticleAdenovirus-Mediated Transduction with Human Glial Cell Line-Derived Neurotrophic Factor Gene Prevents 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Dopamine Depletion in Striatum of Mouse Brain
References (30)
- et al.
Biochem. Biophys. Res. Commun.
(1995) - et al.
Neurosci. Lett.
(1994) - et al.
Brain Res.
(1995) - et al.
Developmental Brain Res.
(1996) - et al.
Neurosci. Res.
(1984) - et al.
J. Chromatogr.
(1990) - et al.
Biochem. Biophys. Res. Commun.
(1997) - et al.
Science
(1993) - et al.
Nature
(1995) - et al.
Nature
(1995)
J. Comp. Neurol.
Proc. Natl. Acad. Sci. U.S.A.
Nucleic Acids Res.
Proc. Natl. Acad. Sci. U.S.A.
Cited by (54)
Neurotrophic factors for the treatment of Parkinson's disease
2011, Cytokine and Growth Factor ReviewsNeurotrophic factor therapy for Parkinson's disease
2010, Progress in Brain ResearchCitation Excerpt :Similar studies have been conducted in parkinsonian mice. For example, Kojima and colleagues found that Ad-GDNF delivered to the striatum of MPTP-treated mice was able to increase striatal DA levels 1 week post-lesion when compared to controls (Kojima et al., 1997). While previous studies had utilized the first-generation E1/E3 defective recombinant virus to deliver GDNF to the parkinsonian brain, in 2004 studies began to assess the efficacy of the E1, E3/E4 defective recombinant Ad-GDNF (Do et al., 2004), which was shown to be less toxic and elicit a lower inflammatory response (Dedieu et al., 1997).
Viral vectors for neurotrophic factor delivery: A gene therapy approach for neurodegenerative diseases of the CNS
2010, Pharmacological ResearchResponse of aged parkinsonian monkeys to in vivo gene transfer of GDNF
2009, Neurobiology of DiseaseCitation Excerpt :GDNF cannot cross the blood brain barrier and, thus, requires intracerebral delivery by direct protein delivery using cannulas and pumps or viral gene transfer. Evidence of GDNF neuroprotective effects by either of these methods has been collected in numerous studies using PD animal models (Ai et al., 2003; Choi-Lundberg et al., 1997; Eslamboli et al., 2003; Grondin et al., 2003; Kishima et al., 2004; Kojima et al., 1997; Kozlowski et al., 2000; Kordower et al., 2000; Mandel et al., 1999; Sautter et al., 1998; Tseng et al., 1997). Based on these data, clinical trials for direct intracerebral protein infusion were started yet their results have been controversial.
Preclinical development of gene therapy for Parkinson's disease
2008, Experimental Neurology
- 1
To whom correspondence should be addressed. Fax: (81) 574-67-5310. E-mail: [email protected].